Difference between revisions of "Ruxolitinib (Jakafi)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Chronic lymphocytic leukemia (CLL/SLL) medications" to "Category:Chronic lymphocytic leukemia medications") |
|||
| Line 20: | Line 20: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 11/16/2011: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm280155.htm Initial FDA approval] for treatment of patients with intermediate or high-risk [[Myelofibrosis | myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis]]. | * 11/16/2011: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm280155.htm Initial FDA approval] for treatment of patients with intermediate or high-risk [[Myelofibrosis | myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis]]. | ||
| − | * 12/4/2014: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425677.htm | + | * 12/4/2014: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425677.htm Indication expanded] for the treatment of patients with [[Polycythemia vera|polycythemia vera (PV)]] who have had an inadequate response to or are intolerant of [[Hydroxyurea (Hydrea)|hydroxyurea (HU)]]. ''(New disease entity)'' |
| + | * 5/24/2019: Indication expanded for steroid-refractory acute [[Graft_versus_host_disease|graft-versus-host disease (GVHD)]] in adult and pediatric patients 12 years and older. ''(New condition)'' | ||
==Also known as== | ==Also known as== | ||
Revision as of 20:27, 24 May 2019
General information
Class/mechanism: Kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][3]
Diseases for which it is used
- Acute myeloid leukemia
- Chronic lymphocytic leukemia (CLL/SLL)
- Hypereosinophilic syndrome
- Myelofibrosis
- Polycythemia vera
Patient drug information
- Patient information may be found in the Ruxolitinib (Jakafi) package insert[1]
- Ruxolitinib (Jakafi) patient drug information (Chemocare)[4]
- Ruxolitinib (Jakafi) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 11/16/2011: Initial FDA approval for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
- 12/4/2014: Indication expanded for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea (HU). (New disease entity)
- 5/24/2019: Indication expanded for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. (New condition)
Also known as
- Code name: INCB018424
- Generic name: ruxolitinib phosphate
- Brand names: Jakafi, Jakavi